A 14-year-old male is being seen by the PMHNP two weeks after initiation of an SSRI for moderate major depressive disorder. His parents report that he has become more irritable and restless over the past few days and express concern about the FDA black box warning on antidepressants. The patient denies suicidal ideation but acknowledges feeling "wound up" and having difficulty sleeping. The PMHNP considers the appropriate monitoring framework for this patient. Which of the following most accurately reflects the clinical implications of the FDA black box warning for antidepressants in pediatric patients?